Baader Bank Aktiengesellschaft Has $1.83 Million Stock Position in Stryker Co. (NYSE:SYK)

Baader Bank Aktiengesellschaft grew its stake in Stryker Co. (NYSE:SYK) by 25.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 5,085 shares of the medical technology company’s stock after buying an additional 1,031 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Stryker were worth $1,831,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Dunhill Financial LLC raised its stake in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the period. Centennial Bank AR lifted its stake in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 48 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in Stryker during the 3rd quarter worth approximately $36,000. Hara Capital LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $42,000. Finally, HBW Advisory Services LLC acquired a new stake in shares of Stryker in the third quarter valued at approximately $42,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $390.98 on Thursday. The business has a 50 day moving average of $376.44 and a 200-day moving average of $361.98. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a 1 year low of $314.05 and a 1 year high of $406.19. The company has a market capitalization of $149.05 billion, a P/E ratio of 41.91, a P/E/G ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same period last year, the company earned $3.46 EPS. On average, equities research analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is currently 36.01%.

Insider Buying and Selling at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday. Royal Bank of Canada upped their price objective on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday. Piper Sandler reissued an “overweight” rating and issued a $420.00 price objective (up previously from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Finally, Citigroup lifted their price target on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $413.45.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.